Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials-Reference-Cited by-同舟云学术

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials

Author:

Savic RM¹,Weiner M²³,MacKenzie WR⁴,Engle M³,Whitworth WC⁴,Johnson JL⁵⁶,Nsubuga P⁶,Nahid P⁷⁸,Nguyen NV⁸,Peloquin CA⁹,Dooley KE¹⁰,Dorman SE¹⁰,

Affiliation:

1. University of California San Francisco School of Pharmacy; San Francisco California USA

2. Veterans Administration Medical Center; San Antonio Texas USA

3. University of Texas Health Science Center; San Antonio Texas USA

4. Centers for Disease Control and Prevention; Atlanta Georgia USA

5. Case Western Reserve University School of Medicine and University Hospitals Case Medical Center; Cleveland Ohio USA

6. Uganda-Case Western Reserve University Research Collaboration; Kampala Uganda

7. University of California San Francisco School of Medicine; San Francisco California USA

8. National Tuberculosis Program; Hanoi Vietnam

9. College of Pharmacy and Emerging Pathogens Institute; University of Florida; Gainesville Florida USA

10. Johns Hopkins University School of Medicine; Baltimore Maryland USA

Funder

United States Division of Tuberculosis Elimination

National Center for HIV/AIDS

Viral Hepatitis

STD

TB Prevention

Centers for Disease Control and Prevention

Veterans Administration

National Center for Advancing Translational Sciences

National Institutes of Health

Clinical and Translational Science Award

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference26 articles.

1. Centers for Disease Control and Prevention Web site Tuberculosis: data and statistics http://www.cdc.gov/tb/statistics/default.htm 2013

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献